COMPAZINE
LOE ApproachingNDAORALCAPSULE, EXTENDED RELEASE
Approved
Jun 1957
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COMPAZINE (prochlorperazine) is an oral extended-release small molecule antipsychotic and antiemetic approved in 1957. The specific indications are not documented in the data provided, but it is historically used for nausea, vomiting, and psychiatric conditions. It functions as a dopamine antagonist with antiemetic and neuroleptic properties.
LOE Approaching
As LOE approaches, brand team size and investment are likely contracting; roles focus on transition planning and generic coordination rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COMPAZINE offers limited career growth; the product is in decline with minimal linked job openings and approaching loss of exclusivity. Professionals on this team develop expertise in generic transition, cost containment, and market maintenance rather than launch or expansion.
Brand ManagerField Sales Representative
Worked on COMPAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.